Dec 03, 2019
Tower Arch Capital Partners with OSM Worldwide to Fuel Next Phase of Growth
Nov 11, 2019
NKMax America Announces Executive Advisory Board
Nov 11, 2019
Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting
Nov 08, 2019
Latest Developments in the Interleukin-2 (IL-2) Research and Development, 2019 Report
Nov 07, 2019
Partner Therapeutics (PTx) Announces the Appointment of John McManus as Chief Business Officer
Oct 28, 2019
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019
Sep 19, 2019
ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases
Sep 19, 2019
Partner Therapeutics Receives Orphan Drug Designation for Leukine® (sargramostim)
Sep 12, 2019
ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article
Sep 05, 2019
ZyVersa Therapeutics Advances Development of Lead Inflammasome Inhibitor Candidate, IC 100
Aug 28, 2019
EMD Serono to Showcase Scientific Leadership at ECTRIMS 2019 with New Data Across Multiple Sclerosis Medicines
Aug 20, 2019
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
Jul 17, 2019
PA5051 Shows 3-Fold Decrease In Body Fat And 5-Fold Increase In IL-6 Confirming Its Support For Weight Management
Jun 05, 2019
Kanazawa University Research: Discovery of a Molecule Facilitating Cancer Diagnosis
May 28, 2019
EMD Serono to Present Data at CMSC Annual Meeting Showcasing Breadth of MS Portfolio and Commitment to Understanding How MS Impacts Patients
May 21, 2019
Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
Apr 30, 2019
EMD Serono to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Apr 22, 2019
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Apr 01, 2019
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Mar 26, 2019
New Study Points to SX-682 as Strategy to Boost Immunotherapy Effectiveness in Advanced Colorectal Cancer